Pratikkumar Asari

Pratikkumar Asari

Auto-generated profile, based on publicly available information

Pratikkumar Asari


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2026 in Journal of Hospital Pharmacy and Health Services
Verified
Journal Article
Open access
CACamila Kaori Aihara
Camila Kaori Aihara
LVLigia Cássia Val
Ligia Cássia Val
NANatália Morici Aoki
Natália Morici Aoki
FRFabiana Roveda
Fabiana Roveda
PAPratikkumar Asari
Pratikkumar Asari
NTNaba Kumar Talukdar
Naba Kumar Talukdar
Objective: To evaluate the bioequivalence of the two formulations of Eurofarma’s Levetiracetam 750 mg Extended Release Coated Tablets (Test Product [T]) against Keppra XR (Reference Product [R]) in healthy adults under fasting and fed conditions. Methods: The studies were designed as open, randomized, balanced, two treatments, two-period, single dose, crossover under fasting and fed condition with seven days washout interval. The assigned subjects were given test tablets and reference tablets in each period orally at a dose of 750 mg under fasting and fed conditions. Each study involved 32 subjects. In both the studies under fasting and fed conditions, the major pharmacokinetic parameters were calculated by SAS® Software 9.4 and the bioequivalence was evaluated. Results: For bioequivalence evaluation a total of 31 subjects completed the fasting study, and 29 subjects completed the fed study. The 90% confidence intervals for the geometric mean ratios of Levetiracetam area under the curve (AUC0-T and AUC0-∞) and maximum plasma concentration (Cmax ) were within the established bioequivalence limits of 80% to 125%. A total of three adverse events were reported during the conduct of the two studies, with one event possibly related to the study medication and the other two considered unrelated. All adverse events were mild to moderate in severity and did not significantly impact the participants’ quality of life. No serious adverse events were reported. Conclusion: It can be concluded that the two formulations can be used interchangeably.